Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vomiting Clear all
Completed Phase 3 Interventional

A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip

NCT02462850
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Jul 21, 2026, 8:04 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chemoradiation-Induced Nausea and Emesis: Quality of Life

NCT00394602
View directory record Official record
Conditions
Gastric Cancer, Pancreatic Cancer, Cervical Cancer, Vulvar Cancer, Endometrial Cancer, Anal Cancer
Interventions
Interview, Questionnaire
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Heartfulness Meditation (HFM) in Cyclic Vomiting Syndrome (CVS)

NCT05961995
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
Heartfulness meditation
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Results available

Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy

NCT00734929
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant + Dexamethasone, Ondansetron + Dexamethasone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 21, 2026, 8:04 PM EDT
Withdrawn Not applicable Interventional

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

NCT00699894
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
aprepitant 40 mg, ondansetron 4 mg
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 25 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Accupressure of P6 to Reduce Nausea During Cesarean Section

NCT04799587
View directory record Official record
Conditions
Pregnancy Related, Cesarean Delivery, Nausea, Vomiting
Interventions
Magnet at P6, Magnet applied to arm not at P6 pressure point.
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

NCT01504711
View directory record Official record
Conditions
Gastrointestinal Cancer, Nausea Post Chemotherapy
Interventions
fosaprepitant dimeglumine
Drug
Lead sponsor
Philip Philip
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Inhalation Intervention for Nausea in the Emergency Department

NCT02092441
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Alcohol prep pad group, Normal Saline prep pad
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Jul 21, 2026, 8:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

NCT01031953
View directory record Official record
Conditions
Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fosaprepitant dimeglumine, systemic chemotherapy, survey administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Multi-day Doses in Prevention of Nausea and Emesis

NCT00600353
View directory record Official record
Conditions
Myeloma, Plasma-Cell, Lymphoma, Malignant
Interventions
Palonosetron, Aprepitant, Dexamethasone
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 1 Interventional Results available

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

NCT00819039
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Ondansetron
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jul 21, 2026, 8:04 PM EDT
Terminated No phase listed Observational

Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Survey

NCT01378351
View directory record Official record
Conditions
Dysfunction of Vestibular System, Nausea Persistent, Vomiting
Interventions
Questionnaire survey
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Jul 21, 2026, 8:04 PM EDT
Completed No phase listed Observational Results available

Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia

NCT02602080
View directory record Official record
Conditions
Nausea, Emesis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Jul 21, 2026, 8:04 PM EDT
Active, not recruiting No phase listed Observational

Cardiac Vagal Effects of GES in Patients With Gastroparesis and Vagal Nerve Action Potentials in Vagus Nerve

NCT02159586
View directory record Official record
Conditions
Gastroparesis
Interventions
gastric electrical stimulator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 2 Interventional

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions
GW679769, Dexamethasone, Ondansetron Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Jul 21, 2026, 8:04 PM EDT
Withdrawn Not applicable Interventional

Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy

NCT01980160
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Activated Nometex Device, Unactivated Nometex Device
Device
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 100 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transcutaneous Electroacupuncture for Gastroparesis

NCT01469286
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
TEA, Sham-TEA
Device
Lead sponsor
Transtimulation Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Jackson, Mississippi • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Jul 21, 2026, 8:04 PM EDT
Recruiting Not applicable Interventional

Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.

NCT07063979
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Bariatric Sleeve Gastrectomy
Interventions
Wearable Transcutaneous electrical Nerve Stimulation unit to mitigate postoperative nausea and vomiting (PONV) in the Bariatric Surgical Patient, A sham device that will mimic the active wearable device. It will look the same, and buzz but will not actually admit a low-leve electric current that would stimulate the nerves.
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

NCT01500226
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

NCT06899217
View directory record Official record
Conditions
Idiopathic Gastroparesis
Interventions
CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
85
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

NCT01474915
View directory record Official record
Conditions
Postoperative Nausea and Vomiting (PONV), Nausea
Interventions
Aprepitant, Ondansetron, Promethazine, Dexamethasone
Drug
Lead sponsor
Sergio Bergese
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

NCT00381862
View directory record Official record
Conditions
Colorectal Cancer, Nausea and Vomiting
Interventions
aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Savannah, Georgia • Hilo, Hawaii • Harvey, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 21, 2026, 8:04 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

NCT00306735
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Palonosetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Beech Grove, Indiana • New York, New York • Winston-Salem, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jul 21, 2026, 8:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cortical Excitability in Cyclic Vomiting Syndrome

NCT05256160
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
TMS Paired-Pulse assessment of cortical excitability, Autonomic activity
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 21, 2026, 8:04 PM EDT